Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Timothy Rolph. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Timothy Rolph har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:AKRO / Akero Therapeutics, Inc. Chief Scientific Officer 0
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Timothy Rolph. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Timothy Rolph som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-12-09 2025-12-09 4 AKRO Akero Therapeutics, Inc.
Common Stock
D - Sale to Issuer -43.810 0 -100,00
2025-12-09 2025-12-09 4 AKRO Akero Therapeutics, Inc.
Common Stock
D - Sale to Issuer -238.339 0 -100,00
2025-11-28 2025-11-25 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 4.739 282.149 1,71 21,10 99.993 5.953.344
2025-11-28 2025-11-25 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 94.268 277.410 51,47 0,62 57.975 170.607
2025-11-28 2025-11-25 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 2.796 183.142 1,55 0,62 1.720 112.632
2025-11-28 2025-11-25 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 4.284 180.346 2,43 21,09 90.350 3.803.497
2025-11-28 2025-11-25 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 43.064 176.062 32,38 6,36 274.059 1.120.459
2025-11-28 2025-11-25 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 3.527 132.998 2,72 28,35 99.990 3.770.493
2025-11-19 2025-11-17 4 AKRO Akero Therapeutics, Inc.
Common Stock
G - Gift -37.100 129.471 -22,27
2025-10-09 2025-10-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -1.037 166.571 -0,62 46,82 -48.554 7.799.187
2025-10-09 2025-10-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -11.463 167.608 -6,40 46,01 -527.447 7.712.147
2025-10-09 2025-10-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 12.500 179.071 7,50 28,35 354.375 5.076.663
2025-09-12 2025-09-11 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -553 166.571 -0,33 43,02 -23.790 7.165.884
2025-09-10 2025-09-08 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -34 167.124 -0,02 44,88 -1.526 7.499.690
2025-09-10 2025-09-08 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -12.466 167.158 -6,94 44,17 -550.611 7.383.202
2025-09-10 2025-09-08 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 295 179.624 0,16 28,35 8.363 5.092.340
2025-09-10 2025-09-08 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 5.161 179.329 2,96 6,36 32.845 1.141.250
2025-09-10 2025-09-08 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 7.044 174.168 4,21 21,09 148.558 3.673.203
2025-08-07 2025-08-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -6.962 167.124 -4,00 49,49 -344.577 8.271.635
2025-08-07 2025-08-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -5.538 174.086 -3,08 49,06 -271.722 8.541.530
2025-08-07 2025-08-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 12.500 179.624 7,48 21,09 263.625 3.788.270
2025-07-09 2025-07-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -41 167.124 -0,02 52,62 -2.157 8.793.564
2025-07-09 2025-07-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -1.825 167.165 -1,08 52,00 -94.893 8.691.911
2025-07-09 2025-07-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -10.634 168.990 -5,92 50,93 -541.611 8.606.999
2025-07-09 2025-07-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 12.500 179.624 7,48 21,09 263.625 3.788.270
2025-07-02 2025-06-30 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 890 167.124 0,54 23,87 21.243 3.988.916
2025-06-20 2025-06-18 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -1.129 166.234 -0,67 54,84 -61.914 9.116.273
2025-06-12 2025-06-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -2.358 167.363 -1,39 54,00 -127.323 9.036.933
2025-06-09 2025-06-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -25.000 169.721 -12,84 55,04 -1.376.000 9.341.444
2025-06-09 2025-06-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 389 194.721 0,20 21,10 8.208 4.108.613
2025-06-09 2025-06-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 24.611 194.332 14,50 21,09 519.046 4.098.462
2025-06-09 2025-06-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.150 169.721 -1,82 53,84 -169.596 9.137.779
2025-06-09 2025-06-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -9.350 172.871 -5,13 53,37 -499.038 9.226.644
2025-06-09 2025-06-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 12.500 182.221 7,37 21,10 263.750 3.844.863
2025-05-08 2025-05-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -300 169.721 -0,18 44,50 -13.351 7.553.094
2025-05-08 2025-05-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -8.650 170.021 -4,84 43,87 -379.476 7.458.821
2025-05-08 2025-05-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.550 178.671 -1,95 42,26 -150.037 7.551.351
2025-05-08 2025-05-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 12.500 182.221 7,37 21,10 263.750 3.844.863
2025-04-28 2025-04-24 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -6.250 169.721 -3,55 41,03 -256.438 6.963.653
2025-04-28 2025-04-24 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 6.250 175.971 3,68 21,10 131.875 3.712.988
2025-04-10 2025-04-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -200 169.721 -0,12 37,92 -7.583 6.434.972
2025-04-10 2025-04-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -100 169.921 -0,06 36,93 -3.693 6.274.843
2025-04-10 2025-04-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.750 170.021 -2,16 36,05 -135.202 6.129.937
2025-04-10 2025-04-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -2.200 173.771 -1,25 35,36 -77.783 6.143.847
2025-04-10 2025-04-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 6.250 175.971 3,68 21,10 131.875 3.712.988
2025-03-14 2025-03-12 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -516 169.721 -0,30 44,88 -23.158 7.617.078
2025-03-07 2025-03-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.162 170.237 -1,82 44,90 -141.974 7.643.641
2025-03-07 2025-03-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -9.338 173.399 -5,11 44,40 -414.617 7.699.089
2025-03-07 2025-03-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 12.500 182.737 7,34 21,10 263.750 3.855.751
2025-02-07 2025-02-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -5.903 170.237 -3,35 56,92 -336.022 9.690.571
2025-02-07 2025-02-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -12.847 176.140 -6,80 56,32 -723.607 9.921.086
2025-02-07 2025-02-05 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 18.750 188.987 11,01 21,10 395.625 3.987.626
2025-01-29 2025-01-27 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -12.379 170.237 -6,78 56,97 -705.232 9.698.402
2025-01-29 2025-01-27 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -5.059 182.616 -2,70 55,62 -281.382 10.157.102
2025-01-29 2025-01-27 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -13.812 187.675 -6,86 54,76 -756.345 10.277.083
2025-01-29 2025-01-27 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 16.264 201.487 8,78 21,10 343.170 4.251.376
2025-01-29 2025-01-27 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 14.986 185.223 8,80 19,87 297.772 3.680.381
2025-01-10 2025-01-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
G - Gift -14.000 170.237 -7,60
2024-12-30 2024-12-26 4 AKRO Akero Therapeutics, Inc.
Common Stock
G - Gift -14.100 184.237 -7,11
2024-12-18 2024-12-17 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.800 178.337 -2,09 31,10 -118.172 5.545.924
2024-12-18 2024-12-17 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 3.800 182.137 2,13 19,87 75.506 3.619.062
2024-12-18 2024-12-16 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 20.000 198.337 11,21
2024-12-12 2024-12-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -2.450 178.337 -1,36 31,03 -76.024 5.533.797
2024-12-12 2024-12-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 2.450 180.787 1,37 19,87 48.682 3.592.238
2024-12-12 2024-12-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -2.368 178.337 -1,31 30,79 -72.911 5.490.996
2024-09-13 2024-09-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -537 180.705 -0,30 26,18 -14.059 4.730.857
2024-07-02 2024-06-28 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 1.064 181.242 0,59 19,94 21.217 3.614.147
2024-06-13 2024-06-11 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -2.380 180.178 -1,30 22,64 -53.886 4.079.410
2024-03-15 2024-03-13 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -619 182.558 -0,34 28,33 -17.536 5.171.868
2023-12-18 2023-12-14 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -514 182.672 -0,28 20,76 -10.671 3.792.271
2023-12-12 2023-12-08 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 32.497 183.186 21,57
2023-09-25 2023-09-13 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -531 150.689 -0,35 50,34 -26.731 7.585.684
2023-06-21 2023-06-16 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -1.413 151.220 -0,93 56,30 -79.547 8.513.172
2023-06-21 2023-06-16 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -27.462 152.633 -15,25 55,08 -1.512.607 8.407.026
2023-06-21 2023-06-16 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -49.325 180.095 -21,50 54,58 -2.691.912 9.828.685
2023-06-21 2023-06-16 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 40.000 229.420 21,12 0,61 24.400 139.946
2023-06-15 2023-06-13 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -509 189.420 -0,27 55,16 -28.076 10.448.407
2023-03-14 2023-03-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
F - Taxes -603 189.929 -0,32 43,47 -26.212 8.256.214
2022-12-30 2022-12-29 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -12.293 190.532 -6,06 51,38 -631.571 9.788.867
2022-12-30 2022-12-29 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -8.023 202.825 -3,81 50,55 -405.547 10.252.418
2022-12-30 2022-12-29 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 7.816 210.848 3,85 28,35 221.584 5.977.541
2022-12-30 2022-12-28 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -1.700 203.032 -0,83 50,00 -85.006 10.152.372
2022-12-30 2022-12-28 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 1.700 204.732 0,84 28,35 48.195 5.804.152
2022-12-13 2022-12-09 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 19.195 203.032 10,44
2022-11-16 2022-11-16 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -100 183.837 -0,05 46,04 -4.604 8.464.775
2022-11-16 2022-11-16 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.847 183.937 -2,05 45,45 -174.859 8.360.562
2022-11-16 2022-11-15 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.138 187.784 -1,64 45,04 -141.343 8.458.223
2022-10-27 2022-09-13 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -22.500 233.837 -8,78 29,18 -656.550 6.823.364
2022-10-27 2022-09-13 4/A AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 10.000 256.337 4,06 6,36 63.600 1.630.303
2022-10-27 2022-10-26 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -4.762 190.922 -2,43 45,03 -214.433 8.597.218
2022-10-27 2022-10-25 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -10.653 195.684 -5,16 45,09 -480.349 8.823.489
2022-10-27 2022-10-25 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 1.797 206.337 0,88 28,35 50.945 5.849.654
2022-10-27 2022-10-25 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 8.203 204.540 4,18 6,36 52.171 1.300.874
2022-10-07 2022-10-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -22.500 186.337 -10,77 39,29 -884.025 7.321.181
2022-10-07 2022-10-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 10.000 208.837 5,03 21,09 210.900 4.404.372
2022-10-04 2022-09-30 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -22.500 198.837 -10,17 34,06 -766.350 6.772.388
2022-10-04 2022-09-30 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -22.500 221.337 -9,23 31,38 -706.050 6.945.555
2022-10-04 2022-09-30 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 13.672 243.837 5,94 21,09 288.342 5.142.522
2022-10-04 2022-09-30 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 6.328 230.165 2,83 6,36 40.246 1.463.849
2022-09-15 2022-09-13 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -22.500 223.837 -9,13 29,18 -656.550 6.531.564
2022-09-13 2022-06-30 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 1.152 246.337 0,47 8,03 9.251 1.978.086
2022-09-13 2021-06-30 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 1.007 245.185 0,41 21,09 21.238 5.170.952
2021-12-10 2021-12-08 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 87.221 87.221
2020-12-09 2020-12-08 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 77.580 77.580
2020-12-09 2020-06-30 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 1.245 244.178 0,51 17,07 21.250 4.167.630
2020-03-13 2020-03-12 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -22.656 42.796 -34,61
2020-03-13 2020-03-12 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -27.368 94.268 -22,50
2020-03-13 2020-03-12 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 22.656 242.933 10,29 0,61 13.820 148.189
2020-03-13 2020-03-12 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 27.368 220.277 14,19 0,61 16.694 134.369
2019-12-13 2019-12-13 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 85.000 85.000
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
385.818
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
385.818
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
385.818
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)